Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
The Development of China's New Generation Information Technology
Yesterday 11:46 PM
An Entrepreneur and Her New Journey to Globalization
Yesterday 05:40 PM
EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part I）
Yesterday 04:43 PM
Robooter: Structuring New Ecology for Elderly Care
Sep 20, 2023 06:17 PM